Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has been given a consensus rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $15.1667.

A number of analysts have weighed in on the company. UBS Group assumed coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They set a “buy” rating and a $19.00 price target for the company. Weiss Ratings downgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Barclays increased their price target on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. Truist Financial increased their price target on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $13.17 on Friday. The company has a fifty day moving average of $12.62 and a 200-day moving average of $12.92. The company has a market capitalization of $4.20 billion, a PE ratio of 34.66 and a beta of 1.32. Amneal Pharmaceuticals has a 52-week low of $7.07 and a 52-week high of $15.42.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. On average, equities analysts forecast that Amneal Pharmaceuticals will post 0.92 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares in the company, valued at approximately $1,211,960.40. This trade represents a 27.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 17.30% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kemnay Advisory Services Inc. bought a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth about $26,000. Federated Hermes Inc. boosted its position in shares of Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank boosted its position in shares of Amneal Pharmaceuticals by 186.7% during the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Spire Wealth Management boosted its position in shares of Amneal Pharmaceuticals by 66.6% during the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC boosted its position in shares of Amneal Pharmaceuticals by 541.9% during the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.